Do Men Naturally Produce Estrogen? Yes—Here Is How It Works

Yes. Men naturally produce estrogen every day, and not in trivial amounts. The male body makes estradiol through a dedicated enzymatic pathway, and circulating levels sit in a measurable range that supports bone density, brain function, and cardiovascular health. A small fraction of testosterone is converted to estradiol in fat, brain, and bone tissue, while the adrenal glands contribute precursor hormones that peripheral tissues convert into estrogen. Men with aromatase deficiency or estrogen receptor mutations develop serious metabolic and skeletal problems, which shows how much male physiology depends on estrogen.

The aromatase conversion pathway

The central mechanism is a single enzyme: aromatase, encoded by the CYP19A1 gene. Aromatase lives in the endoplasmic reticulum of cells and performs a three-step chemical reaction that removes the methyl group from carbon 10 of testosterone and converts the A-ring of the steroid to an aromatic ring. That is how a C19 androgen becomes an 18-carbon estrogen. The reaction consumes one molecule of oxygen and one NADPH per step, so it is an oxidative process, not a passive leak.

Where does this happen in men? Aromatase is abundant in adipose tissue, which is why body composition matters. It is also expressed in osteoblasts, chondrocytes, brain regions such as the hypothalamus and hippocampus, and testicular Leydig cells. Adipose tissue is the dominant peripheral site. This means men with higher body fat tend to have higher aromatase activity and higher estradiol relative to testosterone, which is a physiological consequence, not a pathology by itself.

The adrenal contribution is separate but important. The adrenal cortex produces dehydroepiandrosterone and androstenedione, weak androgens that peripheral tissues can convert to estrone and then to estradiol. This pathway matters more when testicular production declines. In older men, adrenal precursors and peripheral conversion sustain some estrogen even as testosterone falls. The conversion happens in peripheral tissue, not in the blood, so serum measurements tell you the output, not the tissue-level production rate.

A caveat professionals raise: serum estradiol does not perfectly reflect aromatase activity in the brain. Local estradiol synthesis in the brain from testosterone is increasingly recognized as a distinct compartment. A man with normal serum estradiol can still have different brain-level estrogen dynamics. That gap between circulating and tissue-level estrogen is one reason simple serum thresholds can mislead.

How much estrogen men actually make

Adult men have mean serum estradiol concentrations in the range of 20 to 40 picograms per milliliter when measured by modern immunoassay or mass spectrometry. That is roughly one-tenth to one-twentieth of the typical premenopausal female level, but it is not zero, and it is biologically active. Some men with obesity exceed 50 pg/mL. Total estrone levels in men are higher than estradiol and rise with age.

The conversion fraction is small but measurable. Roughly 0.2 to 0.4 percent of circulating testosterone is aromatized to estradiol in a given passage through tissue. With total testosterone around 500 to 600 nanograms per deciliter, that produces estradiol concentrations in the range above. The fraction stays fairly stable, which is why estradiol tends to track testosterone unless aromatase activity or body composition changes.

Age changes the picture. Testosterone declines slowly, roughly 1 to 2 percent per year after the third decade. Estradiol declines less steeply in many men, and in some studies estradiol rises in older men because adipose tissue increases. The result is a rising estradiol-to-testosterone ratio in men who gain fat with age. This ratio shift, not a single number, is what clinicians interpret.

Edge cases that change the rules

Experimental evidence is unusually clear here for one reason: rare genetic cases. Men with aromatase deficiency have high testosterone and undetectable estradiol. They develop tall stature, unfused growth plates, low bone density, and insulin resistance. Men with estrogen receptor alpha mutations show similar skeletal problems. These phenotypes prove estrogen is required for male bone maturation and metabolic health, which is not obvious from numbers alone.

Obesity is the most common edge case. Because aromatase sits in adipose tissue, higher fat mass means more conversion. One consequence is that estradiol can rise while testosterone falls, producing a low testosterone-to-estradiol ratio. Another is that weight loss reduces aromatase activity. Bariatric surgery studies show estradiol falls after substantial weight loss, sometimes into a lower range than before.

Certain tumors can produce estrogen ectopically. Leydig cell tumors and some testicular germ cell tumors can express aromatase and drive high estradiol, causing gynecomastia. Liver disease matters too, because the liver clears estrogens; cirrhosis can raise estradiol. These are pathological, not normal physiology, but they matter for interpreting an unexpected estradiol result.

Medications alter the pathway. Aromatase inhibitors block conversion and can collapse estradiol in men. Some drugs, including certain antifungals and glucocorticoids, change steroid metabolism indirectly. A professional caveat: an isolated estradiol level rarely justifies treatment; context, including testosterone, body composition, and symptoms, determines whether a finding matters.

Misconceptions worth correcting

Misconception one: estrogen is a female hormone. Estrogen is a human hormone. Men produce it, and male physiology depends on it. The receptor is present in male bone, brain, vascular tissue, and reproductive tissue.

Misconception two: testosterone converts to estrogen only when something goes wrong. Aromatization is normal and constant. It is the intended pathway, not a malfunction.

Misconception three: high estrogen means feminization will follow. Gynecomastia requires a sustained imbalance and tissue sensitivity, and many men with elevated estradiol have no breast tissue change. The threshold is not a single number.

Misconception four: serum estradiol equals tissue estrogen. As noted, brain and bone estrogen are partly local and partly circulating. A serum measurement is one window, not the whole picture.

Bulleted red flags that warrant medical evaluation: New breast tissue growth, tenderness, or nipple discharge Estradiol far above the expected range with low testosterone Rapid onset of these changes over weeks to months Testicular mass or asymmetry with high estradiol Signs of liver disease alongside altered hormone levels Infertility with abnormal hormone panel results

Practical interpretation steps

If you are reading a lab result, start with the assay. Estradiol is often measured by immunoassay, which has cross-reactivity and imprecision at low concentrations. Mass spectrometry is more accurate in the male range. If a result looks surprising, the first step is confirming the method.

Next, pair estradiol with total testosterone and, if available, free testosterone. Interpret the ratio. Also record body composition and age, because both shift the expected range. A single reading in the 30s is unremarkable; a reading above 60 with symptoms is worth a clinician visit.

For lifestyle steps, evidence supports maintaining a healthy body fat percentage, because adipose tissue is the main aromatase site. Resistance exercise and adequate protein support lean mass. Heavy alcohol intake stresses the liver, which clears estrogens, so moderation is relevant. Sleep matters for the hypothalamic-pituitary-gonadal axis. None of these steps "lower estrogen" directly; they change the substrate and clearance environment.

Limits of what studies show

The honest limit is that male estrogen research is thinner than female estrogen research. Many reference ranges come from small cohorts, and assay methods vary across studies, which makes direct comparison hard. The genetic cases are strong evidence, but they describe extreme states, not typical variation.

What can be concluded with confidence: men produce estradiol through aromatase, the amount is measurable and biologically necessary, and body composition and age shift the balance. What remains uncertain: precise tissue-level production rates, how much local brain synthesis matters in healthy men, and what estradiol threshold should trigger intervention in the absence of symptoms. A clinician should interpret borderline results in context, not as a standalone diagnosis.